Covid QR Codes

Demo Location 1
200 Medical Drive
Carmel, IN 46032

Lab Director: Lab Director Name
CLIA: XXD1234567
Phone: (317) 794-3929

Patient Name			Date of Birth	Gender	Ordering Physician		Client ID
Lindquist, Andrew			1/1/2000	M	Steven, Strange		**Demo Location 1** 200 Medical Drive Carmel, IN 46032
Specimen ID	**Specimen Type**	**Collected Date**	**Received Date**	**Reported Date**		**Passport Number**	
100376	Swab	11/16/2021 1:17:18 PM	11/16/2021 1:19:08 PM	11/16/2021 1:22:51 PM			

TRAVEL QR CODE VALIDATION

This QR code can be shown to any requesting party to retrieve a validated result

COVID-19 RT-PCR		
Test	**Result**	**Comment**
SARS CoV-2 (COVID-19) RT-PCR	Negative	

Notes:

This test has been validated according to the FDA guidelines. Our laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.
section 263a, to perform high complexity tests CLIA#XXD1234567 . This test has not been Food and Drug Administration (FDA) cleared or approved. The assay is submitted for authorization by FDA under an Emergency Use Authorization (EUA). The SARS-CoV-2 test is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in
nasopharyngeal and oropharyngeal swab samples from patients. Testing methodology is real-time PCR. If received as separate collection devices, nasopharyngeal and oro-pharyngeal specimens are combined for analysis. Test results must have clinical correlation with patient history and other diagnostic information necessary to determine patient infection status. Test performance can be affected because the clinical spectrum of infection caused by SARS-CoV-2 is not fully known. SARS-CoV-2 RNA NOT DETECTED. Not Detected results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions.

Negative results must be combined with clinical observations, patient history, and epidemiological information. Not Detected results are concluded based on the inability of
probes annealing to all three (ORF1ab, N gene, S gene) specific SARS-CoV-2 target sequences (from the sample submitted) located between three (3) unique forward and
reverse primers, resulting in no Amplification signals during real-time PCR.

The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Samples must be collected, transported, and stored using appropriate procedures and conditions. Improper collection, transport, or storage of specimens may hinder the ability of the assay to detect the target sequences. SARS-CoV-2 RNA DETECTED. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Detected results are concluded based on the probes annealing to two out of three (ORF1ab, N gene, S gene) specific SARS-CoV-2 target sequences (from the sample submitted) located between three (3) unique forward and reverse primers, resulting in Amplification signals during real-time PCR.

The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Laboratories within the United States and its territories are required
to report all positive results to the appropriate public health authorities.

Samples must be collected, transported, and stored using appropriate procedures and conditions. Improper collection, transport, or storage of specimens may hinder the ability of the assay to detect the target sequences. SARS-CoV-2 RNA INCONCLUSIVE. INCONCLUSIVE results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Inconclusive results must be combined with clinical observations, patient history, and epidemiological information. Inconclusive results are concluded based on detection of only one of three (ORF1ab, N gene, S gene) specific SARS-CoV-2 target sequences. Detection of only one of three (ORF1ab, N gene, S gene) specific SARS-CoV-2 target sequences triggers a recommendation of recollection